Investigating how NSD3 affects lung cancer development
Official title: Role of NSD3 in regulation of cancer pathogenesis
Funded at University of Tx Md Anderson Can Ctr · NIH-11045092 · Data updated 2026-11-12
This study is looking at a protein called NSD3 to see how it affects the growth of lung squamous cell carcinoma, a serious type of lung cancer, with the hope of finding new treatments that could help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $644,553 |
| NIH project number | 5R01CA278940-03 |
| Project ID | NIH-11045092 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with lung squamous cell carcinoma who may benefit from novel therapeutic approaches.
✕Less likely to help
Patients with other types of lung cancer or those without a diagnosis of lung cancer may not receive any benefit from this research.
What this research studies
This research focuses on understanding the role of the NSD3 protein in the development of lung squamous cell carcinoma (LUSC), a common and deadly form of lung cancer. By studying how NSD3 influences cancer progression at the molecular level, the researchers aim to identify new therapeutic targets that could lead to effective treatments. The study utilizes advanced mouse models that mimic human cancer to explore the mechanisms by which NSD3 contributes to tumor growth and metastasis. Patients may benefit from the findings as they could lead to the development of targeted therapies for LUSC, which currently lacks approved treatment options.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for lung squamous cell carcinoma, improving treatment options for patients.
How similar studies have gone: Previous research has shown promise in targeting epigenetic factors in cancer treatment, suggesting that this approach could be beneficial.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Mazur, Pawel K. — University of Tx Md Anderson Can Ctr
- Study coordinator: Mazur, Pawel K.
Related research
Other NIH-funded projects on the same topics.
-
HIV-related cervical cancer screening and care in LMICs (AVANÇO HAMRC)
A multi-country effort to build sustainable research infrastructure and low-cost cervical cancer screening and treatment methods for women living with HIV in Brazil and Mozambique.
-
HIV-associated cervical cancer care infrastructure in LMICs
A program to build sustainable research infrastructure and bring low-cost cervical cancer screening, diagnosis, and treatment to women with HIV in Brazil and Mozambique.
-
HIV-associated cervical cancer screening and care network in LMICs
A multinational program aims to build affordable, practical cervical cancer screening, diagnosis, and treatment methods for women living with HIV in Brazil and Mozambique.
-
Mapping HIV-like SIV Reservoirs in the Brain with Advanced PET Imaging
This project develops brain-targeted imaging probes to map SIV reservoirs in the central nervous system of infected macaques, aiming to improve our understanding of how HIV-like viruses hide in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Germline clues to skin-related immune side effects from cancer immunotherapy
This grant looks for genetic clues in people treated with immune checkpoint inhibitors to understand why some develop skin-related immune side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.